| All patients (n = 211) | 1st line (n = 85) | 2nd line (n = 78) | ≥ 3rd line (n = 48) |
---|---|---|---|---|
Best response | Â | Â | Â | Â |
 Partial response | 46(21.8) | 23(27.1) | 17(21.8) | 6(12.5) |
 Stable disease | 145(68.7) | 58(68.2) | 53(67.9) | 34(70.8) |
 Progressive disease | 20(9.5) | 4(4.7) | 8(10.3) | 8(16.7) |
Objective response rate | 46(21.8) | 23(27.1) | 17(21.8) | 6(12.5) |
Disease control rate | 191(90.5) | 81(95.3) | 70(89.7) | 40(83.3) |
Progression-free rate | Â | Â | Â | Â |
 6 months | 136(64.5) | 59(69.4) | 43(55.1) | 34(70.8) |
 12 months | 65(30.8) | 33(38.8) | 21(26.9) | 11(22.9) |
Survival outcome (months) | Â | Â | Â | Â |
 Median PFS (95% CI) | 12.2(10.1–14.3) | 14.5(11.1–17.9) | 10.6(4.1–17.1) | 8.7(6.8–10.7) |